Ask Warren

Pangen Biotech

222110 · KOSDAQ · ₩222110 · 팬젠

₩4,285▼ ₩325 (7.05%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩4B₩3.7B₩2.5B₩4B₩3.5B₩3.4B₩4.3B₩4.6B
Cost of sales₩2.8B₩2.1B₩2.2B₩3.1B₩1.9B₩1.7B₩3.5B₩2.3B
Gross profit₩1.1B₩1.7B₩283M₩938M₩1.6B₩1.7B₩860M₩2.3B
Operating income−₩220M₩482M−₩404M₩377M₩833M₩701M−₩277M₩1.3B
Net income−₩48M₩751M−₩102M₩532M₩885M₩736M−₩512M₩1.2B
Net income to shareholders−₩48M₩751M−₩102M₩532M₩885M₩736M−₩512M₩1.2B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩33B₩33B₩33B₩33B₩37B₩31B₩31B₩25B
Current assets₩24B₩24B₩23B₩23B₩28B₩21B₩21B₩15B
Cash and equivalents₩3B₩3.7B₩3.8B₩3.2B₩9B₩2.1B₩1.4B₩2.1B
Total liabilities₩2.5B₩2.8B₩2.8B₩2.7B₩7.4B₩5.3B₩5.6B₩7.4B
Current liabilities₩2.5B₩2.7B₩2.7B₩2.7B₩4.5B₩2.4B₩2.9B₩4.6B
Borrowings₩0₩1B₩962M₩923M₩886M₩850M₩816M₩2.3B
Total equity₩31B₩31B₩30B₩30B₩29B₩26B₩25B₩18B
Shareholders' equity₩31B₩31B₩30B₩30B₩29B₩26B₩25B₩18B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩933M−₩719M₩887M−₩3.7B₩3.2B−₩254M₩1B₩779M
Capital spending₩527M₩26M₩129M₩196M₩46M₩191M₩310M₩9.3M
Free cash flow₩406M−₩745M₩758M−₩3.9B₩3.2B−₩445M₩693M₩770M

Consolidated where available. Amounts in won.

Also known as: Pangen Biotech / 팬젠 / 222110 / KRX:222110

Source: KRX statistical information